ACST Stock – (NASDAQ: ACST) is actually giving an update on the usage
As necessary pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or maybe the “Company”) ACST Stock (NASDAQ: ACST – TSX-V: ACST) is actually giving an update on the usage of the “at the market” equity of its providing program.
As earlier disclosed, Acasti entered into an amended and restated ATM sales agreement on June 29, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and H.C. Co. and Wainwright, LLC (collectively, the “Agents”), to put into practice a “at the market” equity offering program under which Acasti may issue as well as market from time to time its everyday shares having an aggregate offering price of up to $75 million in the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as required pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the final distributions reported on January 27, 2021, Acasti granted an aggregate of 20,159,229 typical shares (the “ATM Shares”) with the NASDAQ Stock Market for aggregate gross proceeds to the Company of US$21.7 zillion. The ATM Shares ended up being sold at prevailing market prices averaging US$1.0747 a share. No securities were marketed through the facilities of the TSXV or, to the knowledge of the Company, in Canada. The ATM Shares were offered pursuant to a U.S. registration statement on Form S 3 (No. 333-239538) as made effective on July seven, 2020, as well as the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate gross proceeds raised was paid to the Agents in connection with the services of theirs. As a consequence of the latest ATM sales, Acasti has a total of 200,119,659 common shares issued and great as of March five, 2021.
The additional capital raised has strengthened Acasti’s balance sheet and often will deliver the Company with more freedom in its ongoing review process to enjoy and evaluate strategic options.
About Acasti – ACST Stock
Acasti is actually a biopharmaceutical innovator that has historically centered on the research, commercialization and development of prescribed drugs using OM3 fatty acids delivered both as free fatty acids and bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have extensive clinical proof of efficacy as well as safety for lowering triglycerides in people with HTG. CaPre, or hypertriglyceridemia, an OM3 phospholipid therapeutic, was being created for patients with severe HTG.
Forward Looking Statements – ACST Stock
Statements of that press release which aren’t statements of current or historical fact constitute “forward-looking information” within the meaning of Canadian securities laws as well as “forward-looking statements” to the meaning of U.S. federal securities laws (collectively, “forward looking statements”). Such forward-looking assertions include known and unknown risks, uncertainties, and other unknown components that might cause the particular outcomes of Acasti to be materially different from historical results and from any later results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe these types of risks as well as uncertainties, people are actually urged to look at statements marked with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or any other related expressions to be uncertain and forward-looking. Readers are actually cautioned not to place undue reliance on these forward looking statements, which speak just as of the day of this particular press release. Forward-looking claims in that press release include, but are not confined to, information or statements about Acasti’s strategy, succeeding operations as well as the review of its of strategic options.
The forward-looking claims found in this press release are expressly qualified in the entirety of theirs by this alerting declaration, the “Special Note Regarding Forward-Looking Statements” area contained in Acasti’s newest annual report on Form 10 K and quarterly report on Form 10 Q, which are readily available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at www.sedar.com and also on the investor aisle of Acasti’s site at www.acastipharma.com. All forward looking claims in this press release exist as of the day of this particular press release.
ACST Stock – Acasti does not undertake to upgrade any such forward looking statements whether as a direct result of info that is brand new , future events or otherwise, except as called for by law. The forward-looking assertions contained herein are also subject generally to risks and assumptions as well as uncertainties that are actually described from time to time in Acasti’s public securities filings with the Securities as well as exchange Commission and The Canadian securities commissions, including Acasti’s newest annual report on Form 10-K and quarterly report on Form 10 Q under the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is providing an update on the use